Delivering Unprecedented Access to Biosimilars in Global Markets
  • Developing, Manufacturing and Commercializing
    Biosimilar Products for Global Markets
Who We Are

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Learn More

News & Events

March 25, 2015

EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30

March 24, 2015

EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results 

Bookmark and Share